Sex Differences in Lung Cancer.

Cancers (Basel) · 2023 · PMC10296433 · PMID 37370722

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A recent trial showed a trend of females receiving osimertinib (a third-generation epidermal growth factor receptor tyrosine kinase inhibitor) having improved survival over males; however, this result was not statistically significant [ 135 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.